Osimertinib combined with bevacizumab as the first‐line treatment in non‐small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations

BACKGROUND: The efficacy and safety of osimertinib combined with bevacizumab in non‐small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) mutations have not been fully studied. METHODS: Treatment‐naïve NSCLC patients with brain metastasis har...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ling, You, Yunhong, Liu, Xueli, Liu, Fengjuan, Nie, Keke, Ji, Youxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212661/
https://www.ncbi.nlm.nih.gov/pubmed/37016906
http://dx.doi.org/10.1111/1759-7714.14880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212661/
https://www.ncbi.nlm.nih.gov/pubmed/37016906
http://dx.doi.org/10.1111/1759-7714.14880

Ejemplares similares